The Health division of Wolters Kluwer, a leading global provider of information and point of care solutions for the healthcare industry, announced today that customers can access the newly-released Affordable Care Act Federal Upper Limit drug pricing benchmark, or ACA FUL, through two solutions from its Wolters Kluwer Clinical Drug Information business unit.
The Medi-Span® application line from Clinical Drug Information is widely considered the industry leader in providing drug pricing data, attributes, and analysis. Wolters Kluwer Clinical Drug Information is providing ACA FUL data through two Medi-Span offerings:
- Medi-Span Federal Government Pricing File – Database provides the monthly value of ACA FUL, plus the Weighted Average Manufacturer’s Price (AMP), upon which the Centers for Medicare and Medicaid Services (CMS) is basing ACA FUL calculations.
- Medi-Span® Price Rx – Online drug pricing analysis tool will feature ACA FUL among the many price types included in its Product Information Reports. It will be available for inclusion in Custom Reports at a later date.
Published by CMS, ACA FUL is based on a new formula detailed in the Affordable Care Act. CMS anticipates it will be used to establish reimbursement for drugs covered under Medicaid. It will eventually replace the long-standing CMS FUL pricing type.
“For nearly two years, the Clinical Drug Information team has been monitoring development of ACA FUL and preparing for its release so that there would be little to no gap for healthcare professionals and businesses requiring efficient access to the data,” said Denise Basow, MD, President & CEO of Clinical Effectiveness at Wolters Kluwer. “Medi-Span offerings continue to be the standard for timely drug product and pricing data that help drive business processes and intelligence gathering for the nation’s top PBMs, pharmaceutical manufacturers, retail pharmacies, and healthcare organizations.”